EyePoint Pharmaceuticals Inc (NASDAQ: EYPT) is -4.41% lower on its value in year-to-date trading and has touched a low of $2.21 and a high of $30.99 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The EYPT stock was last observed hovering at around $22.81 in the last trading session, with the day’s loss setting it -0.72%.
Currently trading at $22.09, the stock is -17.21% and -13.15% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.89 million and changing -3.16% at the moment leaves the stock 57.26% off its SMA200. EYPT registered 759.53% gain for a year compared to 6-month gain of 96.01%. The firm has a 50-day simple moving average (SMA 50) of $16.83 and a 200-day simple moving average (SMA200) of -$11.23.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -25.65% loss in the last 1 month and extending the period to 3 months gives it a 10.62%, and is -14.18% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 7.58% over the week and 7.29% over the month.
EyePoint Pharmaceuticals Inc (EYPT) has around 121 employees, a market worth around $1.10B and $46.02M in sales. Profit margin for the company is -153.84%. Distance from 52-week low is 899.55% and -28.72% from its 52-week high. The company has generated returns on investments over the last 12 months (-26.10%).
EyePoint Pharmaceuticals Inc quarterly earnings per share for the current quarter are estimated at -$0.41 with sales reaching $9.92M over the same period.The EPS is expected to grow by 3.13% this year, but quarterly earnings will post 1.60% year-over-year. Quarterly sales are estimated to grow 29.10% in year-over-year returns.
193 institutions hold shares in EyePoint Pharmaceuticals Inc (EYPT), with institutional investors hold 105.07% of the company’s shares. The shares outstanding are 49.04M, and float is at 46.59M with Short Float at 12.29%. Institutions hold 103.99% of the Float.
The top institutional shareholder in the company is Franklin Resources, Inc. with over 5.06 million shares valued at $44.06 million. The investor’s holdings represent 14.48% of the EYPT Shares outstanding. As of Jun 29, 2023, the second largest holder is Essex Woodlands Management Inc. with 4.19 million shares valued at $36.46 million to account for 11.98% of the shares outstanding. The other top investors are Suvretta Capital Management, LLC which holds 3.42 million shares representing 9.79% and valued at over $29.79 million, while RA Capital Management, L.P. holds 9.63% of the shares totaling 3.37 million with a market value of $29.32 million.
EyePoint Pharmaceuticals Inc (EYPT) Insider Activity
The most recent transaction is an insider sale by Jones David Scott, the company’s SVP & Chief Commercial Officer. SEC filings show that Jones David Scott sold 209 shares of the company’s common stock on Feb 02 ’24 at a price of $28.49 per share for a total of $5954.0. Following the sale, the insider now owns 37962.0 shares.
EyePoint Pharmaceuticals Inc disclosed in a document filed with the SEC on Jan 26 ’24 that Paggiarino Dario A. (Chief Medical Officer) sold a total of 49,325 shares of the company’s common stock. The trade occurred on Jan 26 ’24 and was made at $25.66 per share for $1.27 million. Following the transaction, the insider now directly holds 36505.0 shares of the EYPT stock.
Still, SEC filings show that on Jan 26 ’24, Jones David Scott (SVP & Chief Commercial Officer) disposed off 26,017 shares at an average price of $25.38 for $0.66 million. The insider now directly holds 37,962 shares of EyePoint Pharmaceuticals Inc (EYPT).
